Baseline characteristics by trial arm at recruitment
| . | Intervention (n = 18) . | Control (n = 17) . | All participants (N = 35) . |
|---|---|---|---|
| Age, y (SD) | 32.67 (5.09) | 30.94 (6.14) | 31.83 (5.61) |
| Parity | |||
| Primiparous, n (%) | 10 (55.6%) | 7 (41.2%) | 17 (48.6%) |
| Previous miscarriage | 4 (22.2%) | 3 (17.3%) | 7 (20%) |
| Previous stillbirth | 0 | 1 (5.9%) | 1 (2.8%) |
| BMI, kg/m2 (SD) | 26.29 (4.88) | 27.59 (6.53) | 26.90 (5.66) |
| Gestation in weeks at recruitment (SD) | 14.44 (3.09) | 13.87 (3.15) | 14.16 (3.09) |
| Clinical disease | |||
| HbSS, n (%) | 11 (61.1%) | 10 (58.8%) | 21 (60.0%) |
| HbSC, n (%) | 6 (33.3%) | 6 (35.3%) | 12 (34.3%) |
| Sβ-thalassemia, n (%) | 1 (5.6%) | 1 (5.9%) | 2 (5.7%) |
| . | Intervention (n = 18) . | Control (n = 17) . | All participants (N = 35) . |
|---|---|---|---|
| Age, y (SD) | 32.67 (5.09) | 30.94 (6.14) | 31.83 (5.61) |
| Parity | |||
| Primiparous, n (%) | 10 (55.6%) | 7 (41.2%) | 17 (48.6%) |
| Previous miscarriage | 4 (22.2%) | 3 (17.3%) | 7 (20%) |
| Previous stillbirth | 0 | 1 (5.9%) | 1 (2.8%) |
| BMI, kg/m2 (SD) | 26.29 (4.88) | 27.59 (6.53) | 26.90 (5.66) |
| Gestation in weeks at recruitment (SD) | 14.44 (3.09) | 13.87 (3.15) | 14.16 (3.09) |
| Clinical disease | |||
| HbSS, n (%) | 11 (61.1%) | 10 (58.8%) | 21 (60.0%) |
| HbSC, n (%) | 6 (33.3%) | 6 (35.3%) | 12 (34.3%) |
| Sβ-thalassemia, n (%) | 1 (5.6%) | 1 (5.9%) | 2 (5.7%) |
Intervention arm consists of serial prophylactic exchange transfusion; control arm consists of standard care.
BMI, body mass index, HbSC, hemoglobin SC disease; HbSS, sickle cell hemoglobinopathy.